Team:Tsinghua/Safety

From 2012.igem.org

(Difference between revisions)
Line 1: Line 1:
 +
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<head>
-
<title></title>
 
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
-
<style type="text/css">td img {display: block;}</style>
+
<title>无标题文档</title>
-
<!--Fireworks CS5 Dreamweaver CS5 target. Created Sat Apr 14 20:15:24 GMT+0800 2012-->
+
<script src="http://code.jquery.com/jquery-1.8.1.min.js"></script>
-
<style type="text/css">
+
-
p{
+
-
font-family:Arial, Helvetica, sans-serif
+
-
}
+
-
        strong{font-family:Arial, Helvetica, sans-serif;
+
-
font-size:16px}
+
-
h2{
+
-
font:"Courier New", Courier, monospace;
+
-
font-size:24px;
+
-
text-decoration:none;
+
-
text-shadow:#333;
+
-
text-transform:capitalize;
+
-
+
-
color:#005E8A;
+
-
}
+
 +
<script type="application/javascript">
 +
$("document").ready(function(){
 +
$("div[pID=1]").click(function(){
 +
 +
$(this).animate({left:'-=2', top:'-=2',width:'+=4',height:'+=4'}, 'fast');
 +
$(this).animate({left:'+=2', top:'+=2',width:'-=4',height:'-=4'}, 'fast');
-
#search-controls {
+
});
-
position: absolute;
+
});
-
top:  20px;
+
$("document").ready(function(){
-
right: 15px;
+
-
width: 150px;
+
-
height: 40px;
+
-
background-color: transparent;
+
-
    text-align: center;
+
-
    z-index: 3;
+
-
}
+
-
input.searchButton {
+
-
margin: 1px 10px 0 10px;
+
-
font-size: 100%;
+
-
background: none;
+
-
border: none;
+
-
color: #FFFFFF;
+
-
font-weight: bold;
+
-
}
+
-
input.searchButton:hover {
+
-
color: E0E0E0;
+
-
}
+
-
#searchInput {
+
-
    width: 10.9em;
+
-
    margin: 0;
+
-
    font-size: 95%;
+
-
}
+
-
#menubar {
+
});
-
    position: absolute;
+
-
    white-space: nowrap;
+
-
    top: -6px;
+
-
    width: 400px;
+
-
    z-index: 5;
+
-
    font-family: sans-serif;
+
-
    font-size: 95%;
+
-
    line-height: 1em;
+
-
}
+
-
.left-menu, .left-menu a {
+
//onLoad!
-
    left: 0px;
+
var pageStatus = 0;//0 for safetyDesign; 1 for safetyQuestions
-
    text-align: left;
+
$("document").ready(function(){
-
    color: #000000;
+
$("#safetyDesign").slideToggle();
-
    opacity:0.6;
+
});
-
    text-transform: lowercase;
+
-
}
+
-
.left-menu:hover {
+
function showA(K){
-
    color: white;
+
-
    background-color: #000000;
+
-
    opacity:0.6;
+
-
}
+
-
.right-menu, .right-menu a {
+
-
    right: 0px;
+
-
    text-align: right;
+
-
    color: white;
+
-
}
+
-
#menubar ul {
+
-
    color: #000000;
+
-
    list-style: none;
+
-
}
+
-
#menubar li {
+
-
    display: inline;
+
-
    position: relative;
+
-
    cursor: pointer;
+
-
    padding-left: 0px;
+
-
    padding-right: 0px;
+
-
}
+
-
.left-menu li a {
+
-
    padding: 0px 10px 0px 0px;
+
-
}
+
-
.left-menu .selected {
+
-
    color: white;
+
-
}
+
-
#.left-menu .selected:hover {
+
-
    color: #5555FF;
+
-
}
+
-
.left-menu:hover a {
+
if (pageStatus == 1 && K == 0){
-
    color: white;
+
 +
$("#safetyQuestion").slideToggle(700, function(){
 +
$("#safetyDesign").slideToggle();
 +
pageStatus = 0;});
 +
 +
}else if(pageStatus == 0 && K == 1){
 +
$("#safetyDesign").slideToggle(700, function(){
 +
$("#safetyQuestion").slideToggle();
 +
 +
pageStatus = 1;});
 +
 +
}
 +
}
 +
 
 +
</script>
 +
 
 +
<style type="text/css">
 +
/*hack*/
 +
 
 +
body{
 +
background-color:#FFFFFF;}
 +
 
 +
#content{
 +
border:none;
 +
/**TODO*/
}
}
-
.right-menu li {
+
#catlinks{
-
    background-color: transparent;
+
visibility:hidden;
-
}
+
-
.right-menu li a {
+
-
    padding: 0px 15px 0px 0px;
+
-
    color: white;
+
-
    background-color: transparent;
+
-
}
+
-
.right-menu li a:hover {
+
-
    color: #aaaaff;
+
-
    text-decoration: underline;
+
-
}
+
-
.Ks{
+
-
padding-top:25px;
+
-
padding-bottom:25px;
+
-
padding-right:50px;
+
-
padding-left:50px;
+
-
background:#FCFCFC;
+
}
}
 +
.firstHeading{visibility:hidden}
-
</style>
+
/*hack*/
-
<script type="text/javascript" language="JavaScript1.2">
+
a{
-
var item_count = 5;
+
text-decoration:none;
-
var image_over = new Array(item_count);
+
color:#000000;
-
var image_down = new Array(item_count);
+
}
-
var image_normal = new Array(item_count);
+
a:hover{
-
function init(){
+
text-decoration:none;
-
//完成预先载入过程
+
color:#000000;
-
preLoadButtonImage();
+
}
 +
a:link{
 +
}
 +
a:active{
 +
}
 +
a:visited{
}
}
-
function preLoadButtonImage(){
 
-
//记录导航菜单的项目数
 
-
//var image_over = new Array(item_count);
 
-
//var image_down = new Array(item_count);
 
-
var i = 0;
 
-
for (i = 0; i < image_over.length; i++){
 
-
image_normal[i] = new Image();
 
-
image_over[i] = new Image();
 
-
image_down[i] = new Image();
 
-
}
 
-
image_normal[0].src = "https://static.igem.org/mediawiki/2012/e/ed/HOME_NAVI.gif";
 
-
image_normal[1].src = "https://static.igem.org/mediawiki/2012/4/40/Project_NAVI.gif";
 
-
image_normal[2].src = "https://static.igem.org/mediawiki/2012/4/43/TEAM_NAVI.gif";
 
-
image_normal[3].src = "https://static.igem.org/mediawiki/2012/1/1e/NOTEBOOK_NAVI.gif";
 
-
image_normal[4].src = "https://static.igem.org/mediawiki/2012/2/25/Safety_easy.png";
 
-
 
-
+
div#BannerCleaner{
-
image_over[0].src = "https://static.igem.org/mediawiki/2012/e/ef/HOME_NAVI_OVER.gif";
+
position:absolute;
-
image_over[1].src = "https://static.igem.org/mediawiki/2012/4/48/Project_NAVI_OVER.gif";
+
top:-99px;
-
image_over[2].src = "https://static.igem.org/mediawiki/2012/4/45/TEAM_NAVI_OVER.gif";
+
left:0px;
-
image_over[3].src = "https://static.igem.org/mediawiki/2012/5/58/NOTEBOOK_NAVI_OVER.gif";
+
z-index:1;
-
image_over[4].src = "https://static.igem.org/mediawiki/2012/d/da/Safety_over.png";
+
width:100%;
 +
height:300px;
 +
border:none;
 +
background:#FFFFFF;
 +
display:block;
 +
}
 +
div#Header{
 +
position:absolute;
 +
z-index:2;
 +
top:-99px;
 +
left:0px;
 +
width:977px;
 +
height:306px;
 +
background:#32B4EB;
 +
}
 +
div.buttom{
 +
position:absolute;
 +
width:196px;
 +
height:73px;
 +
display:block;
 +
background:#C3C;
 +
cursor:pointer;
 +
overflow:hidden;
 +
}
 +
div.buttomHome{
 +
position:absolute;
 +
left: 433px;
 +
top: 217px;
 +
width: 110px;
 +
height: 157px;
 +
display:block;
 +
background:#C3C;
 +
cursor:pointer;
 +
overflow:hidden;
 +
}
 +
div.buttom:hover{
 +
position:absolute;
 +
width:196px;
 +
height:73px;
 +
display:block;
 +
background:#C3C;
 +
opacity:0.7;
 +
filter:alpha(opacity = 70);
 +
overflow:hidden;
 +
cursor:pointer;
 +
}
 +
div.buttomHome:hover{
 +
position:absolute;
 +
left: 433px;
 +
top: 217px;
 +
width: 110px;
 +
height: 157px;
 +
display:block;
 +
background:#C3C;
 +
opacity:0.7;
 +
filter:alpha(opacity = 70);
 +
overflow:hidden;
 +
cursor:pointer;
 +
}
 +
div.buttom img{
 +
position:relative;
 +
width:100%;
 +
height:100%;
 +
}
 +
div.buttomHome img{
 +
position:relative;
 +
width:100%;
 +
height:100%;
 +
}
 +
.content0{
 +
position:absolute;
 +
top:393px;
 +
left:158px;
 +
width:820px;
 +
height:auto;
 +
display:none;
 +
background:#FFFFFF;
 +
opacity:0.8;
 +
filter:alpha(opacity = 80);
 +
/*border-left-width:1;*/
 +
}
 +
.content0:hover{
 +
/*position:absolute;
 +
top:509px;
 +
left:1px;
 +
width:977px;
 +
height:auto;*/
 +
/*display:block;*/
 +
background:#F6F2F0;
 +
opacity:0.8;
 +
filter:alpha(opacity = 80);
 +
}
 +
#ground{
 +
width:100%;
 +
height:800px;
 +
background:#FFFFFF;
 +
}
 +
.imgBarBeforeLoad{
 +
position:absolute;
 +
top:387px;
 +
left:-978px;
 +
width:977px;
 +
height:128px;
 +
z-index:0;
 +
opacity:0.8;
 +
filter:opacity(alpha=80);
 +
background:url("umbrella_safety.gif");
 +
background-repeat:no-repeat;
 +
background-position:left;
 +
-moz-background-size:367px 128px;
 +
background-size:367px 128px;
 +
}
 +
.imgBar{
 +
position:absolute;
 +
top:387px;
 +
left:1px;
 +
width:977px;
 +
height:128px;
 +
z-index:0;
 +
opacity:1.0;
 +
filter:opacity(alpha=80);
 +
background:url("umbrella_safety.gif");
 +
background-repeat:no-repeat;
 +
background-position:left;
 +
-moz-background-size:367px 128px;
 +
background-size:367px 128px;
 +
}
-
+
p{
-
image_down[0].src = "https://static.igem.org/mediawiki/2012/1/1e/HOME_NAVI_DOWN.gif";
+
font-family:Tahoma, Geneva, sans-serif;
-
image_down[1].src = "https://static.igem.org/mediawiki/2012/2/27/Project_NAVI_DOWN.gif";
+
font-size:14px;
-
image_down[2].src = "https://static.igem.org/mediawiki/2012/f/f4/TEAM_NAVI_DOWN.gif";
+
}
-
image_down[3].src = "https://static.igem.org/mediawiki/2012/a/a5/NOTEBOOK_NAVI_DOWN.gif";
+
strong{
-
image_down[4].src = "https://static.igem.org/mediawiki/2012/5/5e/Safety_down.png";
+
font-family:Tahoma, Geneva, sans-serif;
 +
font-size:14px;
 +
}
-
+
li{
-
//document.getElementById("Home")[0].src = image_normal[0].src;
+
font-family:Tahoma, Geneva, sans-serif;
-
//alert(document.getElementById("Home").id + " " + document.getElementById("Home").nodeName);
+
font-size:14px;
-
+
-
+
}
}
-
function changeImage_over(obj, pos){
+
#navi{
-
+
position: absolute;
-
obj.src = image_over[pos].src;
+
top: 393px;
 +
left: 8px;
 +
z-index: 2;
 +
width: 138px;
 +
height: 183px;
 +
}
 +
#safetyDesignNavi{
}
}
-
function changeImage_down(obj, pos){
+
#safetyQuestionNavi{
-
obj.src = image_down[pos].src;
+
}
}
-
function changeImage_leave(obj, pos){
+
#safetyDesignNavi:hover{
-
obj.src = image_normal[pos].src;
+
background:#E9F8FC;
 +
}
 +
#safetyQuestionNavi:hover{
 +
background:#E9F8FC;
}
}
-
</script>
+
</style>
</head>
</head>
-
<body bgcolor="#ffffff" onLoad="Javascript:init();">
 
-
<div id="TOP_BAR" style="position: absolute; width: 976px; height: 100px; z-index: 2; left: -1px; top: -100px; background:white">
+
<body>
-
<img src="https://static.igem.org/mediawiki/2012/4/43/TOPBAR_Temp.png" height="100%" width="100%" alt="TOPBAR"/>
+
-
</div>
+
-
<div style="position: absolute; width: 975px; height: 50px; z-index: 1; left: 0px; top: 0px; background:white" id="layer1">
+
<div id = "BannerCleaner"></div>
 +
<div class="Header" id="Header"></div>
 +
<div id = "Home" class = "buttomHome" pID = 1 flag1 = 0><img src="https://static.igem.org/mediawiki/2012/4/43/Home_tsinghua.gif"/></div>
 +
<div id = "Project" class = "buttom" style = "top:217px; left:1px;" pID = 1 flag1 = 0><img src = "https://static.igem.org/mediawiki/2012/3/37/Project_tsinghua.gif"></div>
 +
<div id = "Dataresult" class = "buttom" style = "top:217px; left:215px;" pID = 1 flag1 = 0><img src = "https://static.igem.org/mediawiki/2012/8/8a/Data.gif"></div>
 +
<div id = "Team" class = "buttom" style = "top:217px; left:568px;" pID = 1 flag1 = 0><img src = "https://static.igem.org/mediawiki/2012/a/a7/Team_tsinghua.gif"></div>
 +
<div id = "Safety" class = "buttom" style = "top:217px; left:782px;" pID = 1 flag1 = 0><img src = "https://static.igem.org/mediawiki/2012/6/66/Safety_tsinghua.gif"></div>
-
<table style="display: inline-table;" border="0" cellpadding="0" cellspacing="0" width="975px">
+
<div id = "Notebook" class = "buttom" style = "top:302px; left:1px;" pID = 1 flag1 = 0><img src = "https://static.igem.org/mediawiki/2012/4/49/Notebook_tsinghua.gif"/></div>
 +
<div id = "Model" class = "buttom" style = "top:302px; left:215px;" pID = 1 flag1 = 0><img src = "https://static.igem.org/mediawiki/2012/8/8e/Model_tsinghua.gif"></div>
 +
<div id = "Humanpractice" class = "buttom" style = "top:302px; left:569px;" pID = 1 flag1 = 0><img src = "https://static.igem.org/mediawiki/2012/c/ca/HumanPractice.gif"/></div>
 +
<div id = "Parts" class = "buttom" style = "top:302px; left:782px;" pID = 1 flag1 = 0><img src = "https://static.igem.org/mediawiki/2012/b/b5/Parts_tsinghua.gif"></div>
 +
<div class = "content0" id = "safetyQuestion">
 +
<h2>Safety Questions</h2>
 +
  <p>&nbsp;&nbsp;&nbsp;&nbsp;We have always attached great importance to the bio-safety in our experimental progress. And we have been fully implement experimental safety guidelines to ensure the safety of our teammates and to keep a healthy environment. The strains of Escherichia coli we used are harmless, which are widely used in all kinds of laboratories around the world.We answered the questions about safety on the Safety Page from iGEM(<a href="https://2012.igem.org/Safety">https://2012.igem.org/Safety</a>) as following:</p>
 +
  <p><strong>Q1</strong></p>
 +
  <strong>Would any of your project ideas raise safety issues in terms of:</strong>
 +
 
 +
    <ul type="square">
 +
      <li>researcher safety,</li>
 +
      <li>public safety, or</li>
 +
      <li>environmental safety?</li>
 +
    </ul>
 +
 +
  <p><strong>A1</strong>:Our project is to use E.coli to transport and amplify signals in the media and no serious safety problems will be caused. Firstly, the engineering strains of E.coli are harmless. Secondly, we use ampicillin to select our desired strains, thus only strains with our functional genes can survive. Thirdly, in case of the possible problems, we design a turn-off module in our project to stop the functional part and also add a suicide gene to kill all the bacteria. So we are quite sure that our project will not raise any safety issues in terms of the above problems.</p>
 +
  <p></p>
 +
  <p><strong>Q2</strong></p>
 +
  <p><strong>Do any of the new BioBrick parts (or devices) that you made this year raise any safety issues? If yes,</strong></p>
-
  <tr>
+
    <ul type="square">
-
  <td><img src="https://static.igem.org/mediawiki/2012/5/52/Spacer.gif" width="90" height="1" border="0" alt="" /></td>
+
      <li>did you document these issues in the Registry?</li>
-
  <td><img src="https://static.igem.org/mediawiki/2012/5/52/Spacer.gif" width="108" height="1" border="0" alt="" /></td>
+
      <li>how did you manage to handle the safety issue?</li>
-
  <td><img src="https://static.igem.org/mediawiki/2012/5/52/Spacer.gif" width="92" height="1" border="0" alt="" /></td>
+
      <li>How could other teams learn from your experience?</li>
-
  <td><img src="https://static.igem.org/mediawiki/2012/5/52/Spacer.gif" width="134" height="1" border="0" alt="" /></td>
+
    </ul>
-
  <td><img src="https://static.igem.org/mediawiki/2012/5/52/Spacer.gif" width="1" height="1" border="0" alt="" /></td>
+
-
  <td><img src="https://static.igem.org/mediawiki/2012/5/52/Spacer.gif" width="1" height="1" border="0" alt="" /></td>
+
-
  </tr>
+
-
   <tr>
+
   <p><strong>A2</strong>: No, the parts we used/designed this year do not raise potential</p>
-
  <td><a href="https://2012.igem.org/Team:Tsinghua"><img name="Home" src="https://static.igem.org/mediawiki/2012/e/ed/HOME_NAVI.gif" width="90" height="32" border="0" id="Home" alt="Home" onmouseover="javascript:changeImage_over(this, 0);" onmousedown="javascript:changeImage_down(this, 0);" onmouseleave="javascript:changeImage_leave(this, 0);" onmouseout="javascript:changeImage_leave(this, 0);"/></a></td>
+
  safety issues.
-
  <td><a href="https://2012.igem.org/Team:Tsinghua/Project"><img name="Project" src="https://static.igem.org/mediawiki/2012/4/40/Project_NAVI.gif" width="108" height="32" border="0" id="Project" alt="Project" onmouseover="javascript:changeImage_over(this, 1);" onmousedown="javascript:changeImage_down(this, 1);" ononmouseleave="javascript:changeImage_leave(this, 1);" onmouseout="javascript:changeImage_leave(this, 1);"/></a></td>
+
<p></p>
-
  <td><a href="https://2012.igem.org/Team:Tsinghua/Team"><img name="Team" src="https://static.igem.org/mediawiki/2012/4/43/TEAM_NAVI.gif" width="92" height="32" border="0" id="Team" alt="Team" onmouseover="javascript:changeImage_over(this, 2);" onmousedown="javascript:changeImage_down(this, 2);" onmouseleave="javascript:changeImage_leave(this, 2);" onmouseout="javascript:changeImage_leave(this, 2);"/></a></td>
+
  <p><strong>Q3</strong></p>
-
  <td><a href="https://2012.igem.org/Team:Tsinghua/Notebook"><img name="Notebook" src="https://static.igem.org/mediawiki/2012/1/1e/NOTEBOOK_NAVI.gif" width="134" height="32" border="0" id="Notebook" alt="Notebook" onmouseover="javascript:changeImage_over(this, 3);" onmousedown="javascript:changeImage_down(this, 3);" onmouseleave="javascript:changeImage_leave(this, 3);" onmouseout="javascript:changeImage_leave(this, 3);"/></a></td>
+
  <p><strong>Is there a local biosafety group, committee, or review board at your institution?</strong></p>
-
  <td><a href="https://2012.igem.org/Team:Tsinghua/Safety"><img name="Safety" src="https://static.igem.org/mediawiki/2012/2/25/Safety_easy.png" width="100" height="32" border="0" id="Notebook" alt="Notebook" onmouseover="javascript:changeImage_over(this, 4);" onmousedown="javascript:changeImage_down(this, 4);" onmouseleave="javascript:changeImage_leave(this, 4);" onmouseout="javascript:changeImage_leave(this, 4);"/></a></td>
+
-
  <td><img src="https://static.igem.org/mediawiki/2012/5/52/Spacer.gif" width="200" height="32" border="0" alt="" /></td>
+
-
  </tr>
+
-
</table>
+
 +
    <ul type="square">
 +
      <li>If yes, what does your local biosafety group think about your project?</li>
 +
      <li>If no, which specific biosafety rules or guidelines do you have to consider in your country?</li>
 +
    </ul>
 +
 +
  <p><br />
 +
    <strong>A3</strong>: We do have a local biosafety group in the microbiology lab, which<br />
 +
    had trained our team of distinct aspects before starting lab work,<br />
 +
    including lab safety, waste treatment, potential safety issues in the<br />
 +
    design and etc. During the first few weeks of experiments, at least<br />
 +
    one member of the group would supervise our operation and ensured that<br />
 +
    no research or environment safety problems would occur. Also, we had<br />
 +
    some supervisors/professors from School of Life Sciences, Tsinghua<br />
 +
    University to examine our lab work. They scrutinized by raising<br />
 +
    questions to our member directly as well as by watching us carrying<br />
 +
    out certain procedures. The local biosafety group praised our team for<br />
 +
    the caution on safety issues, and highly approved our design of parts<br />
 +
    that may contribute to improve bioengineering.</p>
 +
    <p></p>
 +
  <p><strong>Q4</strong></p>
 +
  <p><strong>Do you have any other ideas how to deal with safety issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?</strong></p>
 +
  <p><strong>A4</strong>: We believe that the most<strong></strong> incentive way is to establish a corresponding award. This award can be used to reward those teams who build some good bio-security parts or modules. At the same time, to improve the situation, the experience of previous years and some very practical biosafety precautions can be summed up, which can be distributed to the participating teams each year. Also, the heritage on the safe operation within the same school can also be encouraged. Some practical and important safety details can even be published as operation Manual, which will facilitate other teams learning.</p>
</div>
</div>
-
 
+
  <div class="content0" id = "safetyDesign"><p><h2>Our Design For Biosafety</h2>
-
<div class = "Ks">
+
<p>&nbsp;&nbsp;&nbsp;&nbsp;At first, the model bacteria DH5 alpha and BL21(DE3) that we used in our project are harmless. All of the virulence genes have been knocked out. As a result, the bacteria themselves are safe to our researchers and environment.<br />
-
<p>We  have always attached great importance to the bio-safety in our experimental  progress. And we have been fully implement experimental safety  guidelines&nbsp;to ensure the safety of our teammates and to keep a healthy  environment. The strains of Escherichia coli we used are harmless, which are  widely used in all kinds of laboratories around the world.We answered the  questions about safety on the Safety Page from iGEM(<a href="https://2012.igem.org/Safety">https://2012.igem.org/Safety</a>) as following:</p>
+
   Secondly, our part is built in the plasmid which contains antibiotic coding sequence. When the cells are cultured in the LB medium, we will add antibiotic such as ampicillin or kanamycin into the medium. In this way, only the cells that contain our functional part can survive. Once the plasmids are lost, the cells will die.<br />
-
<p><strong>Q1</strong></p>
+
   Thirdly we design the &ldquo;turn-off&rdquo; part which can shut down the expression and the working state of our project just like one power switch of our project. We use the invertase FimE to accomplish this job.</p>
-
<strong>Would any of your project ideas raise safety issues in terms      of: </strong>
+
<p><strong>Introduction of FimE: </strong><br />
-
<ol start="1" type="1">
+
   &nbsp;&nbsp;&nbsp;&nbsp;FimE is one of the invertase that can recognize and then bind with the specific sequence of DNA. We can call the IRL which is the recognition site on the left of target gene and IRR which is on the right. Our idea is to use the nature of FimE to invert the promoter, thus leading to the shut-down of expression, even to the suicide of bacteria. This kind of reverse is inreversible so that we can use this enzyme to make sure that we can stop our part from expression.</p>
-
  <ul type="circle">
+
<p><strong>Stop working!</strong><br />
-
    <li>researcher safety, </li>
+
   &nbsp;&nbsp;&nbsp;&nbsp;Since FimE does exist in the genome of E.coli, we first have<br />
-
    <li>public safety, or </li>
+
   to knock this element out. The next step is to insert FimE into the<br />
-
    <li>environmental safety? </li>
+
   plasmid, downstream of T7 promoter and lac operator, as a part of plasmid backbone. The expression of FimE can be induced by IPTG.<br />
-
  </ul>
+
   We added the following part upstream of every functional part of our experiment, which functions as a switch to shut down its expression, and carrying out other tasks to ensure biosafety. Once FimE is expressed by adding IPTG, it will bind to its specific recognition sequence IRL &amp; IRR, inverting this part. As a result, the promoter is turned to the opposite direction and doesn&rsquo;t make any sense because of the terminator.</p>
-
</ol>
+
<p><img src="../Main/Safety_draft_clip_image002.png" width="522" height="174" /></p>
-
<p><strong>A1</strong>:Our project is to use E.coli to transport and  amplify signals in the media and no serious safety problems will be caused.  Firstly, the engineering strains of E.coli are harmless. Secondly, we use  ampicillin to select our desired strains, thus only strains with our functional  genes can survive. Thirdly, in case of the possible problems, we design a  turn-off module in our project to stop the functional part and also add a  suicide gene to kill all the bacteria. So we are quite sure that our project  will not raise any safety issues in terms of the above problems.</p>
+
<p> <strong>Good-bye, E.coli!</strong><br />
-
<p><strong>Q2</strong></p>
+
&nbsp;&nbsp;&nbsp;&nbsp;In order to prevent some potential problems, we design a module which can directly lead to the <strong>suicide</strong> of bacteria. We use lysozyme as our suicide protein, and put the gene on the upstream of a promoter which has FimE recognition parts on both sides. Since we already have FimE in our designs, which can be directly induced by IPTG, we only need to add IPTG to start the suicide program, and the FimE will bind to the recognition parts to inverse the promoter and express lysozyme. In this way, we can directly kill all the bacteria that may raise safety issues. </p>
-
<p><strong>Do any of the new BioBrick parts (or devices) that you made      this year raise any safety issues? If yes, </strong></p>
+
-
<ol start="1" type="1">
+
-
  <ul type="circle">
+
-
    <li>did you document these issues in the Registry? </li>
+
-
    <li>how did you manage to handle the safety issue? </li>
+
-
    <li>How could other teams learn from your experience? </li>
+
-
  </ul>
+
-
</ol>
+
-
<p><strong>A2</strong>:&nbsp;No,&nbsp;the&nbsp;parts&nbsp;we&nbsp;used/designed&nbsp;this&nbsp;year&nbsp;do&nbsp;not&nbsp;raise&nbsp;potential</p>
+
-
<p>safety&nbsp;issues.
+
-
</p>
+
-
<p>&nbsp;</p>
+
-
<p><strong>Q3</strong></p>
+
-
<p><strong>Is there a local biosafety group, committee, or review board at      your institution? </strong></p>
+
-
<ol start="1" type="1">
+
-
  <ul type="circle">
+
-
    <li>If yes, what does your local biosafety group think about your        project? </li>
+
-
    <li>If no, which specific biosafety rules or  guidelines do you have to consider in your country?</li>
+
-
  </ul>
+
-
</ol>
+
-
 
+
-
<p><br />
+
-
  <strong>A3</strong>:&nbsp;We&nbsp;do&nbsp;have&nbsp;a&nbsp;local&nbsp;biosafety&nbsp;group&nbsp;in&nbsp;the&nbsp;microbiology&nbsp;lab,&nbsp;which<br />
+
-
  had&nbsp;trained&nbsp;our&nbsp;team&nbsp;of&nbsp;distinct&nbsp;aspects&nbsp;before&nbsp;starting&nbsp;lab&nbsp;work,<br />
+
-
  including&nbsp;lab&nbsp;safety,&nbsp;waste&nbsp;treatment,&nbsp;potential&nbsp;safety&nbsp;issues&nbsp;in&nbsp;the<br />
+
-
  design&nbsp;and&nbsp;etc.&nbsp;During&nbsp;the&nbsp;first&nbsp;few&nbsp;weeks&nbsp;of&nbsp;experiments,&nbsp;at&nbsp;least<br />
+
-
  one&nbsp;member&nbsp;of&nbsp;the&nbsp;group&nbsp;would&nbsp;supervise&nbsp;our&nbsp;operation&nbsp;and&nbsp;ensured&nbsp;that<br />
+
-
  no&nbsp;research&nbsp;or&nbsp;environment&nbsp;safety&nbsp;problems&nbsp;would&nbsp;occur.&nbsp;Also,&nbsp;we&nbsp;had<br />
+
-
  some&nbsp;supervisors/professors&nbsp;from&nbsp;School&nbsp;of&nbsp;Life&nbsp;Sciences,&nbsp;Tsinghua<br />
+
-
  University&nbsp;to&nbsp;examine&nbsp;our&nbsp;lab&nbsp;work.&nbsp;They&nbsp;scrutinized&nbsp;by&nbsp;raising<br />
+
-
  questions&nbsp;to&nbsp;our&nbsp;member&nbsp;directly&nbsp;as&nbsp;well&nbsp;as&nbsp;by&nbsp;watching&nbsp;us&nbsp;carrying<br />
+
-
  out&nbsp;certain&nbsp;procedures.&nbsp;The&nbsp;local&nbsp;biosafety&nbsp;group&nbsp;praised&nbsp;our&nbsp;team&nbsp;for<br />
+
-
  the&nbsp;caution&nbsp;on&nbsp;safety&nbsp;issues,&nbsp;and&nbsp;highly&nbsp;approved&nbsp;our&nbsp;design&nbsp;of&nbsp;parts<br />
+
-
that&nbsp;may&nbsp;contribute&nbsp;to&nbsp;improve&nbsp;bioengineering.</p>
+
-
<p><strong>Q4</strong></p>
+
-
<p><strong>Do you have any other ideas how to deal with safety issues that      could be useful for future iGEM competitions? How could parts, devices and      systems be made even safer through biosafety engineering? </strong></p>
+
-
<p><strong>A4</strong>: We believe that the most incentive way is  to establish a corresponding award. This award can be used to reward those  teams who build some good bio-security parts or modules. At the same time, to  improve the situation, the experience of previous years and some very practical  biosafety precautions can be summed up, which can be distributed to the participating  teams each year. Also, the heritage on the safe operation within the same  school can also be encouraged. Some practical and important safety details can  even be published as operation Manual, which will facilitate other teams  learning.</p>
+
-
 
+
-
<p><H2>Our design for biosafety</H2></p>
+
-
<p>At first, the model bacteria DH5 alpha and BL21(DE3) that we used in our project are harmless. All of the virulence genes have been knocked out. As a result, the bacteria themselves are safe to our researchers and environment.<br />
+
-
   Secondly, our part is built in the plasmid which contains antibiotic coding sequence. When the cells are cultured in the LB medium, we will add antibiotic such as ampicillin or kanamycin into the medium. In this way, only the cells that contain our functional part can survive. Once the plasmids are lost, the cells will die.<br />
+
-
   Thirdly we design the &ldquo;turn-off&rdquo; part which can shut down the expression and the working state of our project just like one power switch of our project. We use the invertase FimE to accomplish this job.</p>
+
-
<p><strong>Introduction&nbsp;of&nbsp;FimE:&nbsp;</strong><br />
+
-
   &nbsp;FimE is one of the invertase that can recognize and then bind with the specific sequence of DNA. We can call the IRL which is the recognition site on the left of target gene and IRR which is on the right. Our&nbsp;idea&nbsp;is&nbsp;to&nbsp;use&nbsp;the&nbsp;nature&nbsp;of&nbsp;FimE&nbsp;to&nbsp;invert&nbsp;the&nbsp;promoter,&nbsp;thus  leading&nbsp;to&nbsp;the&nbsp;shut-down&nbsp;of&nbsp;expression,&nbsp;even&nbsp;to&nbsp;the&nbsp;suicide&nbsp;of  bacteria.&nbsp;This kind of reverse is inreversible so that we can use this enzyme to make sure that we can stop our part from expression. </p>
+
-
<p><strong>Stop working!</strong><br />
+
-
   Since&nbsp;FimE&nbsp;does&nbsp;exist&nbsp;in&nbsp;the&nbsp;genome&nbsp;of&nbsp;E.coli,&nbsp;we&nbsp;first&nbsp;have<br />
+
-
   to&nbsp;knock&nbsp;this&nbsp;element&nbsp;out.&nbsp;The&nbsp;next&nbsp;step&nbsp;is&nbsp;to&nbsp;insert&nbsp;FimE&nbsp;into&nbsp;the<br />
+
-
   plasmid,&nbsp;downstream&nbsp;of&nbsp;T7&nbsp;promoter&nbsp;and&nbsp;lac&nbsp;operator,&nbsp;as&nbsp;a  part of plasmid backbone.&nbsp;The&nbsp;expression&nbsp;of&nbsp;FimE&nbsp;can  be&nbsp;induced&nbsp;by IPTG.<br />
+
-
   We&nbsp;added&nbsp;the&nbsp;following&nbsp;part&nbsp;upstream&nbsp;of&nbsp;every&nbsp;functional&nbsp;part&nbsp;of&nbsp;our  experiment,&nbsp;which&nbsp;functions&nbsp;as&nbsp;a&nbsp;switch&nbsp;to&nbsp;shut&nbsp;down&nbsp;its  expression,&nbsp;and&nbsp;carrying&nbsp;out&nbsp;other&nbsp;tasks&nbsp;to&nbsp;ensure&nbsp;biosafety.&nbsp;Once  FimE&nbsp;is&nbsp;expressed&nbsp;by&nbsp;adding&nbsp;IPTG,&nbsp;it&nbsp;will&nbsp;bind&nbsp;to&nbsp;its&nbsp;specific  recognition&nbsp;sequence&nbsp;IRL&nbsp;&amp;&nbsp;IRR,&nbsp;inverting&nbsp;this&nbsp;part.&nbsp;As&nbsp;a&nbsp;result,&nbsp;the  promoter&nbsp;is&nbsp;turned&nbsp;to&nbsp;the&nbsp;opposite&nbsp;direction and doesn&rsquo;t make any sense because of the terminator.</p>
+
-
<p><img width="522" height="174" src="https://static.igem.org/mediawiki/2012/b/b1/PIC1.png" /></p>
+
-
<p>&nbsp;</p>
+
-
<p>Good-bye, E.coli!<br />
+
-
  In order to prevent some potential problems, we design a module which can directly lead to the <strong>suicide</strong> of bacteria. We use lysozyme as our suicide protein, and put the gene on the upstream of a promoter which has FimE recognition parts on both sides. Since we already have FimE in our designs, which can be directly induced by IPTG, we only need to add IPTG to start the suicide program, and the FimE will bind to the recognition parts to inverse the promoter and express lysozyme. In this way, we can directly kill all the bacteria that may raise safety issues.<br />
+
-
  <img width="576" height="97" src="https://static.igem.org/mediawiki/2012/d/d1/PIC2.png" /></p>
+
<p>&nbsp;</p>
<p>&nbsp;</p>
 +
<img src="PIC2[1].png" width="629" height="105" /></p></div>
 +
<div id = "navi" >
 +
  <p id = "safetyDesignNavi"><a href = "javascript:showA(0);">Our Design for Biosafety </a></p>
 +
 
 +
  <p id = "safetyQuestionNavi" ><a href = "javascript:showA(1);">Safety Questions</a></p>
 +
</div>
 +
<div id = "JiaZi" style="position:absolute;width:977px;">
</div>
</div>
-
 
-
 
-
 
</body>
</body>
</html>
</html>
-
nbsp;we
 
-
nbsp;and
 
-
/strong>
 

Revision as of 07:32, 24 September 2012

<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> 无标题文档

Safety Questions

    We have always attached great importance to the bio-safety in our experimental progress. And we have been fully implement experimental safety guidelines to ensure the safety of our teammates and to keep a healthy environment. The strains of Escherichia coli we used are harmless, which are widely used in all kinds of laboratories around the world.We answered the questions about safety on the Safety Page from iGEM(https://2012.igem.org/Safety) as following:

Q1

Would any of your project ideas raise safety issues in terms of:
  • researcher safety,
  • public safety, or
  • environmental safety?

A1:Our project is to use E.coli to transport and amplify signals in the media and no serious safety problems will be caused. Firstly, the engineering strains of E.coli are harmless. Secondly, we use ampicillin to select our desired strains, thus only strains with our functional genes can survive. Thirdly, in case of the possible problems, we design a turn-off module in our project to stop the functional part and also add a suicide gene to kill all the bacteria. So we are quite sure that our project will not raise any safety issues in terms of the above problems.

Q2

Do any of the new BioBrick parts (or devices) that you made this year raise any safety issues? If yes,

  • did you document these issues in the Registry?
  • how did you manage to handle the safety issue?
  • How could other teams learn from your experience?

A2: No, the parts we used/designed this year do not raise potential

safety issues.

Q3

Is there a local biosafety group, committee, or review board at your institution?

  • If yes, what does your local biosafety group think about your project?
  • If no, which specific biosafety rules or guidelines do you have to consider in your country?


A3: We do have a local biosafety group in the microbiology lab, which
had trained our team of distinct aspects before starting lab work,
including lab safety, waste treatment, potential safety issues in the
design and etc. During the first few weeks of experiments, at least
one member of the group would supervise our operation and ensured that
no research or environment safety problems would occur. Also, we had
some supervisors/professors from School of Life Sciences, Tsinghua
University to examine our lab work. They scrutinized by raising
questions to our member directly as well as by watching us carrying
out certain procedures. The local biosafety group praised our team for
the caution on safety issues, and highly approved our design of parts
that may contribute to improve bioengineering.

Q4

Do you have any other ideas how to deal with safety issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?

A4: We believe that the most incentive way is to establish a corresponding award. This award can be used to reward those teams who build some good bio-security parts or modules. At the same time, to improve the situation, the experience of previous years and some very practical biosafety precautions can be summed up, which can be distributed to the participating teams each year. Also, the heritage on the safe operation within the same school can also be encouraged. Some practical and important safety details can even be published as operation Manual, which will facilitate other teams learning.

Our Design For Biosafety

    At first, the model bacteria DH5 alpha and BL21(DE3) that we used in our project are harmless. All of the virulence genes have been knocked out. As a result, the bacteria themselves are safe to our researchers and environment.
Secondly, our part is built in the plasmid which contains antibiotic coding sequence. When the cells are cultured in the LB medium, we will add antibiotic such as ampicillin or kanamycin into the medium. In this way, only the cells that contain our functional part can survive. Once the plasmids are lost, the cells will die.
Thirdly we design the “turn-off” part which can shut down the expression and the working state of our project just like one power switch of our project. We use the invertase FimE to accomplish this job.

Introduction of FimE: 
    FimE is one of the invertase that can recognize and then bind with the specific sequence of DNA. We can call the IRL which is the recognition site on the left of target gene and IRR which is on the right. Our idea is to use the nature of FimE to invert the promoter, thus leading to the shut-down of expression, even to the suicide of bacteria. This kind of reverse is inreversible so that we can use this enzyme to make sure that we can stop our part from expression.

Stop working!
    Since FimE does exist in the genome of E.coli, we first have
to knock this element out. The next step is to insert FimE into the
plasmid, downstream of T7 promoter and lac operator, as a part of plasmid backbone. The expression of FimE can be induced by IPTG.
We added the following part upstream of every functional part of our experiment, which functions as a switch to shut down its expression, and carrying out other tasks to ensure biosafety. Once FimE is expressed by adding IPTG, it will bind to its specific recognition sequence IRL & IRR, inverting this part. As a result, the promoter is turned to the opposite direction and doesn’t make any sense because of the terminator.

Good-bye, E.coli!
    In order to prevent some potential problems, we design a module which can directly lead to the suicide of bacteria. We use lysozyme as our suicide protein, and put the gene on the upstream of a promoter which has FimE recognition parts on both sides. Since we already have FimE in our designs, which can be directly induced by IPTG, we only need to add IPTG to start the suicide program, and the FimE will bind to the recognition parts to inverse the promoter and express lysozyme. In this way, we can directly kill all the bacteria that may raise safety issues.